IMR Press / RCM / Volume 23 / Issue 8 / DOI: 10.31083/j.rcm2308266
Open Access Original Research
Yangxinshi Tablet Improves Exercise Capacity for Patients with Coronary Heart Disease: Results from a Randomized, Double-Blind, Placebo-Controlled, and Multicenter Trial
Show Less
1 Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China
2 Department of Cardiovascular Medicine, Research Center for Translational Medicine, Tongji Hospital Affiliated with Shanghai Tongji University, 200065 Shanghai, China
3 Department of Cardiovascular Medicine, The Jinqiu Hospital of Liaoning Province, 110067 Shenyang, Liaoning, China
4 Department of Cardiovascular Medicine and Cardiac Rehabilitation Center, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, 130000 Changchun, Jilin, China
5 Heart Center, Peking University People's Hospital, 1000044 Beijing, China
*Correspondence: (Xiaoping Meng); (Dayi Hu)
Academic Editors: Kazuhiro P. Izawa and Peter H. Brubaker
Rev. Cardiovasc. Med. 2022, 23(8), 266;
Submitted: 26 April 2022 | Revised: 24 June 2022 | Accepted: 30 June 2022 | Published: 21 July 2022
(This article belongs to the Special Issue Cardiac Rehabilitation—Volume 2)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Objective: To assess the clinical effectiveness of Yangxinshi (YXS) tablets on exercise capacity and symptoms of anxiety and depression in patients with coronary heart disease (CHD). Methods and Results: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed to assess the effects of YXS tablets on exercise capacity and quality of life in patients with CHD. A total of 82 patients were included in this trial. Compared with the placebo group, the YXS group showed significant improvement in peak VO2 (0.22 L/min vs 0.01 L/min; difference 0.1, 95% confidence interval (CI) 0.04–0.16, p = 0.000), peak Mets (0.58 vs 0.09; difference 0.3, 95% CI 0.12–0.47, p = 0.005), anaerobic threshold (AT) VO2 (0.23 L/min vs 0.04 L/min; difference 0.12, 95% CI 0.07–0.18, p = 0.000), AT Mets (0.62 vs 0.16; difference 0.35, 95% CI 0.2–0.5, p = 0.001), and 6 minutes walking test (6MWT) (50.05 m vs 11.91 m; difference 29.92, 95% CI 18.78–41.07, p = 0.000). There were no differences in Hamilton anxiety rating scale (HAM-A score (1.97 vs 2.07; difference 2.03, 95% CI 0.99–3.06, p = 0.926) and Hamilton depression rating scale (HAM-D) score (1.06 vs 1.7; difference1.42, 95% CI 0.24–2.6, p = 0.592). Conclusions: In patients with CHD, YXS tablets, compared with placebo, could improve exercise capacity, without beneficial effects on anxiety and depression symptoms.

Yangxinshi tablets
coronary heart disease
exercise capacity
anxiety and depression
Fig. 1.
Back to top